Suresh S. Ramalingam
Winship Cancer Institute, Emory UniversityAtlanta, GA, USAAuthored Items
David E. Gerber, MD, Martin Reck, Matthew D. Hellmann, Luis Paz-Ares, Hossein Borghaei, Julie Brahmer, Kenneth J. O'Byrne, Prabhu Bhagavatheeswaran, Faith Nathan, Suresh S. Ramalingam
November 9, 2018 | November 2018 Vol 9, NO 11
CheckMate 227 (NCT02477826) is a large phase 3 study of first-line nivolumab or nivolumab-based regimens vs chemotherapy in advanced NSCLC.
Last modified: December 19, 2018